A Phase III Study Of Daunorubicin And Cytarabine +/- G3139 (Genesense, Oblimersen Sodium, NSC 683428, IND 58842), A BCL2 Antisense Oligodeoxynucleotide, In Previously Untreated Patients With Acute Myeloid Leukemia (AML) aged greater than or equal to 60 Years.

Trial Profile

A Phase III Study Of Daunorubicin And Cytarabine +/- G3139 (Genesense, Oblimersen Sodium, NSC 683428, IND 58842), A BCL2 Antisense Oligodeoxynucleotide, In Previously Untreated Patients With Acute Myeloid Leukemia (AML) aged greater than or equal to 60 Years.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Oblimersen (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Apr 2011 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov..
    • 11 Apr 2011 Planned End Date changed to 1 Oct 2016, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top